Hyperhidrosis treatment market seen reaching $950.7 million by 2031

Allied Market Research projects the global hyperhidrosis treatment market will grow from $575.3 million in 2021 to $950.7 million by 2031, driven by rising disease prevalence, new product launches and approvals, and stronger demand for care. North America led the market in 2021, while Asia-Pacific is expected to post the fastest growth through 2031.

Why it matters: - The market outlook points to steady growth in treatments for a condition that affects daily comfort, work and quality of life. - Expanding use of topical therapies and new product development could widen access to treatment options. - The projected growth also signals continued commercial interest from drugmakers and medtech companies targeting hyperhidrosis.

What happened: - Allied Market Research released a report on the global hyperhidrosis treatment market covering type, treatment and age segments. - The report estimates the market generated $575.3 million in 2021 and will reach $950.7 million by 2031. - The forecast implies a 5.1% compound annual growth rate from 2022 to 2031. - The report includes a sample report request and a purchase inquiry page.

The details: - Axillary hyperhidrosis held about three-fifths of the market in 2021 and is expected to remain the largest segment through 2031. - Axillary hyperhidrosis is projected to grow at a 5.4% CAGR during the forecast period. - Topical treatment also accounted for more than three-fifths of the market in 2021 and is expected to keep the largest share through 2031. - Topical treatment is projected to post a 5.4% CAGR, supported by product innovation and rapid effects. - The below-50 age group held around three-fifths of the market in 2021 and is expected to remain the biggest contributor through 2031. - The below-50 segment is projected to grow at a 5.3% CAGR. - North America held more than two-fifths of the market in 2021 and is expected to stay the leading region. - Asia-Pacific is projected to grow at a 5.9% CAGR, the fastest among regions in the report. - The report lists AbbVie, Avanor Healthcare, Brickbell Biotech, Dr August Wolff, Dr. Reddy’s Laboratories, Eirion Therapeutics, Eli Lilly, Hugel, Kaken Pharmaceutical, Intas Pharmaceuticals, Roivant Sciences and Theravida as key players.

Between the lines: - Rising diagnosis and treatment demand in developed markets is doing most of the work behind the forecast. - The report also flags weak awareness and unfavorable reimbursement as restraints, which can slow patient adoption even when products are available. - Covid-19 temporarily hurt treatment volumes as hospitals shifted resources, and some patients turned to self-medication or unconventional methods. - The pandemic also increased depression rates among patients with hyperhidrosis, especially women, and made therapy harder to access.

What’s next: - The market is likely to be shaped by more product launches, new approvals and broader use of topical treatments. - Regional growth will depend on healthcare infrastructure investment, especially in Asia-Pacific. - Companies in the report are expected to keep competing through launches, partnerships and expansion.

The bottom line: - Hyperhidrosis treatment is a modest but expanding global market, with topical therapies, younger patients and North America driving current demand while Asia-Pacific offers the fastest growth potential.